These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9708643)

  • 21. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
    Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD
    Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of amonafide in advanced pancreatic adenocarcinoma.
    Linke K; Pazdur R; Abbruzzese JL; Ajani JA; Winn R; Bradof JE; Daugherty K; Levin B
    Invest New Drugs; 1991 Nov; 9(4):353-6. PubMed ID: 1804812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of amonafide in advanced and recurrent sarcoma patients.
    Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
    Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study.
    Poplin E; Fleming T; MacDonald JS; Eisenberg P; Fisher RI; Conrad ME
    Invest New Drugs; 1993 Feb; 11(1):47-51. PubMed ID: 8349435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
    Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K;
    Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
    Berger MZ; Kris MG; Gralla RJ; Marks LD; Potanovich LM; Dimaggio JJ; Heelan RT
    Am J Clin Oncol; 1991 Apr; 14(2):124-6. PubMed ID: 1851387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
    Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP
    Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
    Gallion HH; Liu PY; Alberts DE; O'Toole RV; O'Sullivan J; Mills G; Smith HO; Hynes HE
    Gynecol Oncol; 1992 Aug; 46(2):230-2. PubMed ID: 1500027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
    O'Dwyer PJ; Paul AR; Hudes GR; Walczak J; Ozols RF; Comis RL
    Invest New Drugs; 1991 Feb; 9(1):65-7. PubMed ID: 2026485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of amonafide in advanced breast cancer.
    Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D
    Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.
    Higano CS; Goodman P; Craig JB; Kish JA; Rivkin SE; Wolf M; Crawford ED
    Invest New Drugs; 1991 Nov; 9(4):361-3. PubMed ID: 1804814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of amonafide in patients with recurrent glioma.
    Levitt R; Buckner JC; Cascino TL; Burch PA; Morton RF; Westberg MW; Goldberg RM; Gallagher JG; O'Fallon JR; Scheithauer BW
    J Neurooncol; 1995; 23(1):87-93. PubMed ID: 7623074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of amonafide dosing based on acetylator phenotype.
    Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
    Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
    Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.
    Kreis W; Chan K; Budman DR; Allen SL; Fusco D; Mittelman A; Hock K; Akerman S; Calabro A; Puccio C; Spigelman M
    Cancer Invest; 1996; 14(4):320-7. PubMed ID: 8689426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
    Ratain MJ; Rosner G; Allen SL; Costanza M; Van Echo DA; Henderson IC; Schilsky RL
    J Clin Oncol; 1995 Mar; 13(3):741-7. PubMed ID: 7884434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of Mitonafide in advanced and relapsed colorectal cancer.
    Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M
    Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced colorectal adenocarcinoma: treatment with amonafide.
    Marschke RF; Wieand HS; O'Connell MJ; Rubin J; Schutt AJ; Burch PA; Kovach JS
    J Natl Cancer Inst; 1994 Jun; 86(12):944-5. PubMed ID: 8196086
    [No Abstract]   [Full Text] [Related]  

  • 39. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
    Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Williams SF; Smiddy J
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):573-9. PubMed ID: 1934870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
    Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
    Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.